We turn breakthrough science into high-value biotherapy companies through a proven, repeatable model.
We systematically identify high-potential biotherapy concepts, rigorously validate their scientific and commercial foundations, and assemble the expertise required to rapidly translate them into differentiated therapeutic products that work.
By leveraging shared infrastructure, centralized capabilities, and an integrated approach to research, product design, early development, IP creation, and regulatory strategy, we advance assets efficiently toward critical value inflection points – supporting sustained, portfolio-wide value creation.
Our model: from lab to partnering readiness
Invent
Our process begins with breakthrough science emerging from leading academic institutions. Each opportunity undergoes rigorous evaluation based on scientific evidence, technology maturity, and patent landscape analysis to ensure freedom to operate and durable competitive advantage. Medical need, clinical relevance, and competitive dynamics are assessed from the outset, ensuring that only scientifically sound, high-impact concepts advance.
Design
Selected therapy concepts are transformed into focused, investment-grade assets through an agile and modular product design process involving clear use-case definition, feasibility studies, strategic collaborations, and disciplined design roadmaps. Dedicated team formation around each asset ensures accountability and execution velocity, while systematic patent generation secures long-term defensibility as design and competitive advantage are refined.
Prove
Assets are advanced through key value-creating milestones under the guidance of an Advisory Board and a strong commitment to data quality and translational rigor. This phase includes proof-of-concept generation, pre-IND studies, and the construction of a robust regulatory and clinical strategy, resulting in credible, partner-ready assets with materially reduced technical and regulatory risk.
Sell
As assets mature, we maximize value through the sale of asset-centric companies to strategic partners. These sales enable disciplined capital recycling, with exit proceeds partially reinvested into the next innovation cycle to continuously expand and strengthen the portfolio.
Where early innovation meets commercial success
Our leadership team brings together decades of scientific excellence, entrepreneurial execution, and hands-on biotherapy development experience. This combination enables early identification of breakthrough opportunities and their systematic conversion into high-value assets.
Operating across shared laboratories, expert teams, and a proven development pathway, our leaders guide each program through a structured progression from academic insight to investment-ready opportunity.
A disciplined approach to biotherapies
Biotherapies that repair, rejuvenate, and enhance tissues for longevity and aesthetic applications.
Immune activators designed to boost efficacy and safety in next-generation cancer, inflammation and immunology treatments.
Targeted radiopharmaceuticals and vectorized chemotherapy delivering therapeutic payloads with precision and reduced risk.
Engineered cell therapies for solid tumors, built for feasibility, manufacturability, and fast translation.